Fig. 5

HMGB1 reversed circHERC1 upregulation-induced cell motility in lung cancer cells. (a) Western blot analysis of HMGB1 expression in NCI-H3255 cells with circHERC1 overexpression or knockdown. (b) qRT‒PCR to determine the level of circHERC1 in NCI-H3255 cells transfected with the control, a circHERC1 overexpression vector, or an HMGB1 knockdown vector and cotransfected with the circHERC1 overexpression vector and the HMGB1 knockdown vector. ***p < 0.001. (c) EdU analysis of the cell proliferation ability of NCI-H3255 cells transfected with the control, a circHERC1 overexpression vector, or an HMGB1 knockdown vector and cotransfected with the circHERC1 overexpression vector and the HMGB1 knockdown vector. *p < 0.05. The scale bar is 25 μm. (d) Wound healing assays to detect cell migration ability of NCI-H3255 cells transfected with the control, a circHERC1 overexpression vector, or an HMGB1 knockdown vector and cotransfected with the circHERC1 overexpression vector and the HMGB1 knockdown vector. **p < 0.01, ***p < 0.001. (e, f) Transwell assay to detect cell migration (e) and invasion (f) in NCI-H3255 cells transfected with the control, a circHERC1 overexpression vector, or an HMGB1 knockdown vector and cotransfected with the circHERC1 overexpression vector and the HMGB1 knockdown vector. ***p < 0.001. (g) Western blot analysis of HMGB1 and the MAPK/ERK, NF-κB and PI3K/AKT pathways in NCI-H3255 cells transfected with the control, a circHERC1 overexpression vector, or an HMGB1 knockdown vector and cotransfected with the circHERC1 overexpression vector and the HMGB1 knockdown vector